Cardio Diagnostics Announces Publication of Study Showing That its PrecisionCHD™ Test Could Save Health Insurers Over $113 Million Annually
Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO) had its price target lowered by analysts at Benchmark Co. from $4.00 to $1.35. They now have a "speculative buy" rating on the stock.
Exponential Health Partners with Cardio Diagnostics to Elevate Cardiovascular Disease Prevention in Michigan
Cardio Diagnostics Holdings, Inc. Enters Into a Nationwide Telehealth Agreement with Navierre
Cardio Diagnostics Holdings, Inc. to Showcase HeartRisk and Actionable Clinical Intelligence Version 3 at the American College of Cardiology’s 73rd Annual Scientific Session